Hematologic Oncology

In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively.

In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies.

Pooled data show PET imaging of metabolic tumor burden at diagnosis helps identify patients most at risk of FL recurrence.

The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.

A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable.

Three year OS was significantly worse compared with the general population, with a persistent risk for relapse.

Follicular large cleaved cell lymphoma is frequently misclassified, according to researchers.

A large prospective analysis of three large cohorts found a positive link between risk for myeloma and cumulative average young adult and adult BMI.

The US Food and Drug Administration has approved blinatumomab (Blincyto) for patients in remission from B-cell precursor ALL with MRD.

In a phase II study, voxtalisib, which targets all four class I PI3Ks, had efficacy in FL but limited clinical effect in MCL, DLBCL, and CLL/SLL.

In this large population-based, case-control study, having ever used a statin was linked to lower risk of total NHL and certain NHL subtypes, including DLBCL.

BET inhibitors CPI-1205 and CPI-0610 have shown promise in two phase I trials in DLBCL and other lymphomas, investigators at TAT 2018 reported.

Recent FDA approval of front-line brentuximab vedotin with chemotherapy in patients with stage III/IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years.

A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies.

Using CRISPR/Cas9 gene editing to remove CD7 from healthy T cells, researchers have found a way to use third party T cells for CAR-T therapy in T-cell hematologic malignancies.

Researchers have discovered that AML cells require high levels of cholesterol for survival, so the cholesterol pathway could represent a potential therapeutic option for the disease.

In this interview, Dr. Frederick Locke discusses the promise of CAR T-cell therapy for lymphomas, and how this gene therapy could offer hope for patients who don't respond to standard treatments.

Researchers report that PD-1/PD-L1 monoclonal blocking antibody allows T cells to remain active and fight malignant evolution, subsequently preventing tumor resistance.

Researchers examined more than 750 pedigrees of familial hematologic malignancies and found that the same genetic alteration may be responsible for Langerhans cell histiocytosis, acute myeloid leukemia, and primary idiopathic myelofibrosis.

FL progression risk at 2 years was twice as high in the high-risk vs the low-risk group, and the gene-expression score may help to guide treatment.

DLBCL patients who received in-hospital chemotherapy had a lower risk of death during hospitalization.

Nearly 80% of R/R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination.

The US FDA has granted Priority Review designation for tisagenlecleucel (Kymriah) for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for, or have relapsed after, ASCT.

A single infusion of the anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel produced durable remissions in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic lymphoma.

Pfizer’s rituximab investigational biosimilar PF-05280586 met the primary endpoint of overall response rate equivalence to rituximab-EU (MabThera) as a frontline treatment for patients diagnosed with CD20-positive follicular lymphoma, the company announced.

A new study demonstrates that it is possible to vaccinate patients with MDS against a decitabine-induced antigen and that the level of induced expression is sufficient to trigger cytotoxicity in patient-derived vaccine-induced T cells.

A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.

PD-L1 expression was more common among patients with the GCB subtype of diffuse large B-cell lymphoma, and PD-L1 positivity predicted shorter survival.

BCR-ABL1 transcript levels at time points within the first year of therapy for CML can best predict the achievement of a deep molecular response.

Treatment with carfilzomib for multiple myeloma was associated with increased incidence of cardiovascular adverse events, especially with higher doses.